Pharmacovigilance

Risk Management Plan(RMP)

A document describing safety activities to identify, characterize, prevent, and minimize risks relating to medicinal products.

Usage Examples

The RMP included additional pharmacovigilance for hepatic events.
Risk minimization measures required prescriber training.
RMP updates were triggered by new safety information.

What is RMP?

A Risk Management Plan (RMP) is a detailed description of the risk management system for a medicinal product. EU legislation requires RMPs for all new marketing authorization applications and may require updates for existing products.

RMPs include: safety specification (important identified risks, potential risks, missing information), pharmacovigilance plan (routine and additional activities), and risk minimization measures (routine and additional measures).

RMPs are living documents updated throughout the product lifecycle. EMA Guideline on Good Pharmacovigilance Practices (GVP) Module V provides RMP format and content requirements.

Regulatory Context

This term appears most often in pharmacovigilance workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside EU GVP MODULE V, DIRECTIVE 2001 83 EC.

FDAEMAWHO

When This Matters

The RMP included additional pharmacovigilance for hepatic events.
Risk minimization measures required prescriber training.
RMP updates were triggered by new safety information.

Common Mistakes

Treating safety signal reviews as periodic instead of continuous.
Not linking new enforcement letters to internal CAPA and labeling workflows.
Using static templates for dynamic benefit-risk communication updates.

Related Regulations

EU GVP MODULE VDIRECTIVE 2001 83 EC

Frequently Asked Questions

RMP is an EU requirement. The US equivalent is REMS (Risk Evaluation and Mitigation Strategy), though not all drugs require REMS. ICH E2E covers pharmacovigilance planning globally.

Activities beyond routine pharmacovigilance to address specific safety concerns, such as post-authorization safety studies (PASS), registries, or active surveillance.